Lack of interleukin-33 and its receptor does not prevent calcipotriol-induced atopic dermatitis-like inflammation in mice.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 04 2020
Historique:
received: 28 01 2020
accepted: 20 03 2020
entrez: 17 4 2020
pubmed: 17 4 2020
medline: 15 12 2020
Statut: epublish

Résumé

Current studies addressing the influence of interleukin-33 or its receptor (IL-33R/ST2) on development of atopic dermatitis-like inflammation in mice have reported conflicting results. We compared the response in single- and double-deficient IL-33

Identifiants

pubmed: 32296080
doi: 10.1038/s41598-020-63410-z
pii: 10.1038/s41598-020-63410-z
pmc: PMC7160114
doi:

Substances chimiques

Il1rl1 protein, mouse 0
Il33 protein, mouse 0
Interleukin-1 Receptor-Like 1 Protein 0
Interleukin-33 0
calcipotriene 143NQ3779B
Calcitriol FXC9231JVH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6451

Références

Bieber, T. Atopic dermatitis. The New England journal of medicine 358, 1483–1494 (2008).
doi: 10.1056/NEJMra074081
Brunner, P. M., Leung, D. Y. M. & Guttman-Yassky, E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 120, 34–41 (2018).
doi: 10.1016/j.anai.2017.09.055
Gittler, J. K. et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. The Journal of allergy and clinical immunology 130, 1344–1354 (2012).
doi: 10.1016/j.jaci.2012.07.012
Moosbrugger-Martinz, V., Schmuth, M. & Dubrac, S. A Mouse Model for Atopic Dermatitis Using Topical Application of Vitamin D3 or of Its Analog MC903. Methods in molecular biology (Clifton, N.J.) 1559, 91–106 (2017).
doi: 10.1007/978-1-4939-6786-5_8
Salimi, M. et al. A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis. Journal of Experimental Medicine 210, 2939–2950 (2013).
doi: 10.1084/jem.20130351
Kim, B. S. et al. TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation. Science Translational Medicine 5, 170ra16–170ra16 (2013).
doi: 10.1126/scitranslmed.3005374
Sundnes, O. et al. Epidermal Expression and Regulation of Interleukin-33 during Homeostasis and Inflammation: Strong Species Differences. J. Invest. Dermatol. 135, 1771–1780 (2015).
doi: 10.1038/jid.2015.85
Pichery, M. et al. Endogenous IL-33 Is Highly Expressed in Mouse Epithelial Barrier Tissues, Lymphoid Organs, Brain, Embryos, and Inflamed Tissues: In Situ Analysis Using a Novel Il-33–LacZ Gene Trap Reporter Strain. The Journal of Immunology 188, 3488–3495 (2012).
doi: 10.4049/jimmunol.1101977
Schmitz, J. et al. IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity 23, 479–490 (2005).
doi: 10.1016/j.immuni.2005.09.015
Savinko, T. et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J. Invest. Dermatol. 132, 1392–1400 (2012).
doi: 10.1038/jid.2011.446
Hueber, A. J. et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. European journal of immunology 41, 2229–2237 (2011).
doi: 10.1002/eji.201041360
Shimizu, M. et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Human molecular genetics 14, 2919–2927 (2005).
doi: 10.1093/hmg/ddi323
Du, H.-Y. et al. The Expression and Regulation of Interleukin-33 in Human Epidermal Keratinocytes: A New Mediator of Atopic Dermatitis and Its Possible Signaling Pathway. J. Interferon Cytokine Res. 36, 552–562 (2016).
doi: 10.1089/jir.2015.0159
Imai, Y. et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc. Natl. Acad. Sci. U.S.A 110, 13921–13926 (2013).
doi: 10.1073/pnas.1307321110
Islam, S. A. & Luster, A. D. T cell homing to epithelial barriers in allergic disease. Nat. Med 18, 705–715 (2012).
doi: 10.1038/nm.2760
Li, M. et al. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. PNAS 103, 11736–11741 (2006).
doi: 10.1073/pnas.0604575103
Li, C. et al. Experimental atopic dermatitis depends on IL-33R signaling via MyD88 in dendritic cells. Cell Death Dis 8, e2735–e2735 (2017).
doi: 10.1038/cddis.2017.90
Chen, Y.-L. et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Science Translational Medicine 11, eaax2945 (2019).
doi: 10.1126/scitranslmed.aax2945
Idrus, Al, A. AnaptysBio’s IL-33 antibody stumbles in midphase eczema trial. fiercebiotech.com Available at, https://www.fiercebiotech.com/biotech/anaptysbio-s-il-33-antibody-stumbles-midphase-eczema-trial ., (Accessed: 3rd March 2020).
Mekada, K. et al. Genetic differences among C57BL/6 substrains. Experimental animals 58, 141–149 (2009).
doi: 10.1538/expanim.58.141
Simon, M. M. et al. A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains. Genome Biol. 14, 1–22 (2013).
doi: 10.1186/gb-2013-14-7-r82
Silver, L. M. Mouse Genetics. (Taylor & Francis US, 1995).
Martin, P. et al. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis research & therapy 15, R13 (2013).
doi: 10.1186/ar4143
Faul, F., Erdfelder, E., Lang, A.-G. & Buchner, A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39, 175–191 (2007).
doi: 10.3758/BF03193146

Auteurs

Wojciech Pietka (W)

K.G. Jebsen Inflammation Research Centre, University of Oslo and Oslo University Hospital, Oslo, Norway.
Department of Pathology, University of Oslo and Oslo University Hospital, Oslo, Norway.

Olav Sundnes (O)

K.G. Jebsen Inflammation Research Centre, University of Oslo and Oslo University Hospital, Oslo, Norway.
Department of Pathology, University of Oslo and Oslo University Hospital, Oslo, Norway.
Department of Rheumatology, Dermatology and Infectious Diseases, University of Oslo and Oslo University Hospital, Oslo, Norway.

Clara Hammarström (C)

Department of Pathology, University of Oslo and Oslo University Hospital, Oslo, Norway.

Manuela Zucknick (M)

Oslo Center for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo and Oslo University Hospital, Oslo, Norway.

Denis Khnykin (D)

K.G. Jebsen Inflammation Research Centre, University of Oslo and Oslo University Hospital, Oslo, Norway.
Department of Pathology, University of Oslo and Oslo University Hospital, Oslo, Norway.

Guttorm Haraldsen (G)

K.G. Jebsen Inflammation Research Centre, University of Oslo and Oslo University Hospital, Oslo, Norway. guttorm.haraldsen@medisin.uio.no.
Department of Pathology, University of Oslo and Oslo University Hospital, Oslo, Norway. guttorm.haraldsen@medisin.uio.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH